BIOKEY (CAYMAN), INC.
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsBioKey (Cayman), Inc. is an early-stage pharmaceutical development and CRO/CDMO platform that became a separate SEC reporting company in 2026 after a partial spin-off from ABVC BioPharma.
What they do
BioKey operates through BK California, a pharmaceutical manufacturing and development company incorporated in California in 2020 and acquired from ABVC in May 2025 for $100. The business describes capabilities in research, formulation development, analytical services, manufacturing, and commercialization of pharmaceutical, nutraceutical and botanical-based products. Its stated assets include proprietary formulations based on botanical extracts such as Maitake mushroom and Polygala tenuifolia. The company says its goal is to further develop CRO/CDMO and commercialization activities, including nutraceutical and functional supplement products.
Revenue drivers
- CRO/CDMO services — The company describes itself as an integrated CRO/CDMO platform with formulation development, analytical services and cGMP manufacturing; no segment revenue breakdown is provided in the excerpt.
- Pharmaceutical product development and manufacturing — BK California is described as a pharmaceutical manufacturing and development company targeting the generic drug market; no revenue figure for this line is given.
- Nutraceutical and botanical products — Management cites nutraceutical and functional supplement products and botanical extract formulations (Maitake mushroom, Polygala tenuifolia) as commercialization targets; the MD&A excerpt states there were no operating revenues for the period presented except for an incomplete sentence.
Recent performance
The 10-Q excerpt states the company had no operating revenues for the period presented, aside from an incomplete reference. At September 30, 2026, total assets were $1.6M against total liabilities of $7.6M, leaving shareholder equity of negative $5.9M. Cash and equivalents stood at $110. The reported balance sheet therefore shows a liquidity position of essentially zero cash against $7.6M in liabilities.
Strategy
Management's stated goal is to further develop CRO/CDMO and commercialization activities, including nutraceutical and functional supplement products, while using existing pharmaceutical development and cGMP manufacturing capabilities. The company completed a separation from ABVC: a Form 10 registration statement became effective June 25, 2026, and a Separation and Distribution Agreement was signed June 22, 2026. On August 21, 2026, ABVC distributed approximately 4,500,000 BioKey Cayman Ordinary Shares, about 15% of shares outstanding, to ABVC shareholders, retaining roughly 85% and remaining controlling shareholder. The excerpt does not describe specific capital investment plans beyond continued development of these activities.
Risks
- Severe liquidity constraint — Cash and equivalents were $110 at September 30, 2026, against $7.6M in total liabilities, indicating minimal near-term funding on hand.
- No operating revenue — The MD&A states the company had no operating revenues for the period presented, so operations are not yet self-funding.
- Controlled by ABVC — ABVC retained approximately 85% of outstanding Ordinary Shares after the August 2026 distribution and remains controlling shareholder, so minority holders have limited influence.
- Recent spin-off and reporting history — BioKey became a separate Exchange Act reporting company only in June 2026 and has since filed 8-Ks for an accountant change (August 6 and 7, 2026) and other events, reflecting a short standalone operating history.
Outlook
Management states its goal is to further develop CRO/CDMO and commercialization activities, including nutraceutical and functional supplement products, while continuing to use existing pharmaceutical development and cGMP manufacturing capabilities. The filing notes the company intends to capitalize on growth opportunities in the generic drug market through BK California. The excerpt does not provide revenue guidance, financing commitments, or a timeline for commercial milestones.